#Nanobodies Market Share | Explore Tumblr Posts and Blogs

nidarsanafwr · 6 months

Text

https://community.wongcw.com/blogs/718208/Nanobodies-Market-Share-Overview-Competitive-Analysis-and-Forecast-2031

Nanobodies Market Share, Overview, Competitive Analysis and Forecast 2031

#NanobodiesMarket #NanobodiesMarketReport #NanobodiesMarketOverview #NanobodiesMarketForecast

0 notes

sabalevaishali · 3 years

Link

Nanobodies Market is estimated to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

The report initiates from the outline of business surroundings and explains the commercial summary of chain structure. Moreover, it analyses forecast By Product Type, By Indication, By Distribution Channel, By Region and Nanobodies Market.

Additionally, this report illustrates the corporate profiles and situation of competitive landscape amongst numerous associated corporations including the analysis of market evaluation and options associated with the worth chain. This report provides valuable insights on the general market profit through a profit graph, an in depth SWOT analysis of the market trends alongside the regional proliferation of this business vertical.

#Nanobodies Market #Nanobodies Market Size #Nanobodies Market Share #Nanobodies Market Trends

0 notes

industry365 · 3 years

Text

Biosensors Market Is Expected To Reach New Growth Revenues During 2021-2028

The global biosensors market size is expected to reach USD 40.53 billion by 2028 according to a new study by Polaris Market Research. The report “Biosensors Market Share, Size, Trends, Industry Analysis Report, By Technology (Thermal, Electrochemical, Piezoelectric, Optical); By Application; By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into the current market dynamics and provides analysis on future market growth.

The introduction of nanotechnology-based biosensors, usage of instruments in blood sugar level monitoring in diabetes patients, increasing demand for home-based point-of-care devices due to the COVID-19 pandemic, increasing advancement in technology, and mounting government policies toward diagnostics are some of the significant factors that may complement the global industry development.

Several new technologies have been developed in recent years which will revolutionize biosensor technology. Nano-biosensors have emerged in recent years, and they are increasingly used in various genomics and proteomic techniques.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/biosensors-market/request-for-sample

The wide application of the product in the medical field will drive the growth of the industry. It is used in various medical section, including drug discovery, blood gas analyzer, cholesterol checking, infectious diseases, and blood glucose monitoring. Such devices are an essential tool in detecting several conditions, from diabetes to cancer, and thus contribute to industry growth.

There are several developments in the global industry in recent times due to its popularity and increased adoption. Fox BIOSYSTEMS launched a white Fox biosensor in March 2021. The biosensor is developed to overcome clogging in samples such as whole blood or lysates. It can detect microvesicles, nanobodies, antibodies, phage, and small molecules, and the probe in this biosensor is based on generic surface chemistry.

The COVID-19 pandemic is expected to further drive the growth of the global industry during the forecast period owing to the adaptation of the product in COVID-19 diagnosis and monitoring. Various companies are developing new COVID-19 associated products at different development levels, and these products are soon expected to be launched in the industry.

Market Participants such as Abbott Laboratories, Bayer AG, AZUR Environmental, Biosensor BV, DuPont Biosensor Materials, Cranfield Biotechnology Centre, Pinnacle Technologies Inc., Johnson & Johnson, Ercon, Inc., EG & IC Sensors, Inc., Strategic Diagnostics, Innovative Biosensors Inc., Sysmex Corporation, LifeScan, Inc., QTL Biosystems, Molecular Devices Corp., and Roche Diagnostics are some of the key players operating in the global market.

Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/biosensors-market/request-for-discount-pricing

Polaris Market Research has segmented the biosensors market report on the basis of product, application, end-use, and region:

Biosensors, Technology Outlook (Revenue – USD Million, 2016 – 2028)

Thermal

Electrochemical

Piezoelectric

Optical

Biosensors, Application Outlook (Revenue – USD Million, 2016 – 2028)

Medical

Food Toxicity

Bioreactor

Agriculture

Environment

Others

Cholesterol

Blood Glucose

Blood Gas Analyzer

Pregnancy Testing

Infectious Testing

Biosensors, End-Use Outlook (Revenue – USD Million, 2016 – 2028)

Home Healthcare Diagnostics

POC Testing

Food Industry

Research Laboratories

Security and Biodefense

Biosensors Market, Regional Outlook (Revenue – USD Million, 2016 – 2028)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Germany

UK

France

Italy

Spain

Austria

Netherlands

China

India

Japan

South Korea

Malaysia

Indonesia

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

Israel

Buy Now: https://www.polarismarketresearch.com/checkouts/9031

0 notes

healthcare-market · 3 years

Text

TMR Analyzes Impact of Outbreak of COVID-19 on Nano Antibodies Market

Global Nano Antibodies Market: Overview

· Nano antibodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments that contain unique structural and functional properties of naturally-occurring heavy chain only antibodies. Nano antibodies, also known as nAb, are single-domain VHH antibodies derived from the Camelidae family of mammals such the llamas, camels, and alpacas.

· Nano antibodies are easier to produce in bulk than polyclonal antibodies. Additionally, these are stable at a range of temperatures and extreme pH levels. Moreover, relatively small size of nano antibodies allows for easy genetic engineering, thereby lowering overall production cost.

Read Report Overview: https://www.transparencymarketresearch.com/nano-antibodies-market.html

Key Drivers of Global Nano Antibodies Market

· Increase in incidence of cancer has induced practitioners and non-specialists to use nano antibodies for practice and surgery. Moreover, in the past few years, nano antibodies have been extensively used in oncology and hematology procedures for the treatment of life-threatening diseases. This is projected to be a key driver of the global nano antibodies market.

· However, nanobodies have significant limitations and disadvantages, which restrains usage. The heavy chain antibodies from which nanobodies are developed can only be obtained from camelids. Traditional monoclonal antibodies, on the other hand, are obtained from mice. Therefore, the development of nano antbodies requires larger, more complicated housing and animal husbandry for obtaining the desired antibody.

Request a Sample of Nano Antibodies Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=71700

North America to Account for Major Share of Global Nano Antibodies Market

· In terms of region, the global nano antibodies market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

· North America is projected to dominate the global market during the forecast period. Rise in prevalence of chronic diseases and increase in investments by leading drug manufacturers in research & development activities that could bring new developments and inventions pertaining to nano antibodies are anticipated to drive the market in the region.

· The market in Asia Pacific is expected to grow at a rapid pace due to increase in investment by emerging markets such as China and India in R&D and surge in health care spending

Pre-book Nano Antibodies Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=71700&ltype=S

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/key-players-in-depression-drugs-market-explore-novel-antidepressants-to-reduce-disease-burden-global-valuation-to-touch-mark-of-us-24-3-bn-tmr-301288569.html

https://www.prnewswire.com/news-releases/significant-rise-in-expenditures-to-improve-the-aesthetic-appeal-of-the-face-spells-growth-in-dermal-fillers-market-product-innovations-to-increase-the-longevity-of-effect-of-fillers-to-amplify-demand-tmr-301293803.html

https://www.prnewswire.com/news-releases/rising-incidence-of-sports-injuries-accidents-during-every-day-functioning-among-the-elderly-underscores-growth-in-adhesive-bandages-market-tmr-301298931.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

rupalic · 3 years

Text

Isoflavones Market: Growth Opportunities and Recent Developments

The global isoflavones market is estimated to be valued at USD 1.2 billion in 2019 and is projected to grow at a CAGR of 4.7% to reach USD 1.5 billion during the forecast period. Growth in this industry is driven by the increasing incidences of chronic diseases, rising prevalence of cancer, technological advancements in the manufacturing of isoflavones, the rapidly increasing geriatric population and so on. By Source, the soy segment is expected to lead the isoflavones market. Prominent dietary sources of isoflavones include soy milk and plant-based alternatives. Several calcium-fortified soy drinks that are rich in fiber and proteins are given preference in countries such as Germany, France, and Switzerland. The consumption of soy isoflavones as food ingredients or food supplements reduces the risk of breast cancer and growth of cancer cells by reducing the cell mitosis process, which fuels the demand for soy as a major source of isoflavones. By application, the pharmaceutical segment is projected to account for the largest share during the forecast period. Based on application, the isoflavones market is segmented into pharmaceuticals, nutraceuticals, cosmetics, and food & beverages. The pharmaceuticals segment accounted for the largest share, owing to its therapeutic and functional properties; isoflavones are used in the treatment for chronic and cardiovascular diseases. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161667005 Key players in isoflavone market include Cargill (Germany), ADM (US), BASF (Germany), DSM (Netherlands), International Flavors and Fragrances (Frutarom) (US), Shanghai Freemen (US), Nexira Inc. (France), Bio-gen Extracts, Sikko Industries, SK Bioland (South Korea), BioMax (India), Avestia Pharma (India), NutraScience Labs (US), Tradichem S.L. (Spain), Nutra Green Biotechnology (China), Herbo Nutra (India), FutureCeuticals Inc. (US), Bio-gen Extracts (US), Xena Bio Herbals Pvt. Ltd. (India), Sikko Industries (India), Biomax (India), and Lactonova (India). North America to lead the market during the forecast period. The North American region accounted for the largest share of the isoflavones market. Increasing cases of obesity in North America increase the focus on weight management techniques & attracting consumers toward healthy and natural food products with natural ingredients, thereby propelling the demand for isoflavones in the region. Market Dynamics Driver: Prevalence of menopausal issues Women in their menopause stage experience various issues such as hot flashes, insomnia, and, in numerous cases, sexual dysfunction. Many women prefer supplements containing estrogen, which may significantly increase the risk of blood clots, stroke, or breast or uterine cancer. Thus, estrogen may not be an option for many women, depending on their health and family health history. Women are currently inclining toward supplements with naturally therapeutic ingredients to manage their menopause symptoms with fewer risks. In response to such changing preferences of women, supplement manufacturers have turned to natural alternatives. They have started utilizing soy isoflavones instead of estrogen, as it mimics the estrogen characteristics and provides estrogen effects that aid in reducing menopausal symptoms such as hot flashes and fatigue. Owing to the rising issues related to menopause and women’s inclination toward supplements with natural alternatives, the demand for isoflavones from the nutraceutical industry is projected to grow in the coming years Restraint: Stringent regulatory requirements Isoflavones come under the active pharmaceutical ingredient (API) category; hence, manufacturers have to follow the rules and regulations imposed for all API products. Pharmaceutical API manufacturers across the globe are witnessing a rise in the demand for APIs, which results in a positive outlook for the market. However, the increasing stringency of regulations is considered as a major restraint that may limit the growth prospects of the market. According to the report, “Fine chemicals stringent regulations prompt return of manufacturing to the west,” published by IHS Chemical Week in January 2015, the demand for APIs is expected to grow at a consistent rate, while the supply of APIs manufactured with international Good Manufacturing Practice (GMP) standards and world-class documentation is not keeping pace with this demand. Opportunity:Emerging technologies Some of the recent advancements in drug development include the use of nanotechnology for the synthesis of APIs. The emergence of nanoparticle technologies for efficient delivery of APIs shows promising potential as a novel and efficient approach. Nanobodies are similar to single-domain antibodies that can bind to specific antigens; however, they are much smaller in size than antibodies. Nanobodies are rapidly becoming an attractive technology platform for pharmaceutical development. Chitosan and Eudragit nanoparticles of Genistein, the predominant isoflavone found in soy products for cancer therapy, have been significantly evaluated for the treatment of chronic diseases in the past few years. The delivery of Genistein-loaded Chitosan and Eudragit S100 loaded polymeric nanoparticles has proven to be a feasible approach to treat cancer. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=161667005 Similarly, bispecific antibodies, which can bind to two different epitopes either on the same or different target, are attracting the attention of market players. Such emerging technologies have the potential to create attractive opportunities for market players. Challenge: Less efficiency compared to alternatives Soy isoflavones can take several weeks or more to reach their maximal benefit. For example, as per Healthline Media (US), a 2015 review found that soy isoflavones take more than 13 weeks to reach just half of their maximum effect. Traditional hormones such as estrogen therapy, on the other hand, take about three weeks to show the same benefit. However, possible adverse effects such as heart attacks and strokes associated with conventional estrogen therapy are projected to enable pharmaceutical and nutraceutical manufacturers to opt for isoflavones derived from natural resources.

0 notes

wiseguy111 · 3 years

Link

Nanobodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments that contain the...

#Nano Antibodies

0 notes

nidarsanafwr · 6 months

Text

https://twikkers.nl/blogs/206034/Nanobodies-Market-Share-Overview-Competitive-Analysis-and-Forecast-2031

Nanobodies Market Share, Overview, Competitive Analysis and Forecast 2031

#NanobodiesMarket #NanobodiesMarketReport #NanobodiesMarketOverview #NanobodiesMarketForecast

0 notes

pharmaphorumuk · 7 years

Text

Sanofi steals in to buy Ablynx for €3.9 billion

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago.

For Sanofi, the acquisition comes hot on the heels of the $11.6bn it spent on Bioverativ last week, reflecting its determination to acquire after missing out on two M&A deals.

However investors are once again less than impressed by Sanofi’s M&A strategy – and whether the price will be ‘a steal’ will depend on Ablynx’s long-term pipeline productivity.

Sanofi’s share price dipped after last week’s Bioverativ takeover news, as investors were concerned the pharma company had overpaid for a haemophilia portfolio which could be overtaken by newer treatments.

Initial reaction to the Ablynx buyout news has also seen a fall in Sanofi’s share price this morning. This reflects concerns that the company has paid too much – the €3.9 billion is three times the market capitalisation of Ablynx in December.

Novo Nordisk has today confirmed it won’t be upping its bid, and will look elsewhere for takeover targets. However the paucity of high quality biotech assets means Novo Nordisk may eventually have to pay higher multiples, as Sanofi has learnt.

The appeal of Ablynx is clear: it is poised to win FDA approval for its first product, rare disease treatment caplacizumab, which could earn $400 million.

Caplacizumab has been developed for acquired Thrombotic Thrombocytopenic Purpura (aTTP), a rare blood disorder, and Sanofi says adding this to its other blood therapies will make it a major player in the growing field.

While caplacizumab is far from being a blockbuster, the approval would validate Ablynx’s proprietary next-generation antibody ‘nanobody’ platform, which could deliver breakthroughs in multiple therapy areas.

Only last summer, Sanofi signed a major €2.4bn R&D deal with Ablynx to use its nanobody technology to develop new immune-related inflammatory disease drugs, and so is already well acquainted with the biotech firm’s capabilities.

The transaction has now been unanimously approved by both the Sanofi and Ablynx boards of directors.

Sanofi’s chief executive Olivier Brandicourt

Sanofi’s chief executive Olivier Brandicourt commented: “With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders.”

Brandicourt said the deal would build on the existing partnership, and indicated that it would not look to close down Ablynx facilities in Belgium. Sanofi has a new biologics manufacturing facility in Geel, and says the Ablynx science centre in Ghent will be maintained and supported.

Ablynx’s chief executive Edwin Moses noted: “Since our founding in 2001, our team has been focused on unlocking the power of our Nanobody technology for patients. The results of our work are validated by clinical data. As we look ahead, we believe Sanofi’s global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline. Our Board of Directors feels strongly that this transaction represents compelling value for shareholders and maximises the potential of our pipeline to the benefit of all stakeholders.”

From a European biotech perspective, the acquisition is a major endorsement of the sector’s ability to produce world-class science, with Belgium among one of the strongest regions for innovative biotech firms.

However the buyout before Ablynx’s first product even reaches the market confirms the difficulty of building ‘big biotech’ in Europe. Investors are usually keen to capitalise at this stage rather than build companies over a longer period, meaning Europe may never produce a company like Amgen or Genentech.

The post Sanofi steals in to buy Ablynx for €3.9 billion appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/sanofi-steals-buy-ablynx-e3-9-billion/

0 notes

rohinic123-blog · 4 years

Text

Osteoarthritis Drugs Market Outlook, Trend, Growth and Share Estimation Analysis

The global osteoarthritis drugs market is witnessing various innovations on the horizons such as rapid pain relieving injections and disease modifying drugs, thanks to growing cases of major illnesses like obesity. The global osteoarthritis is expected to witness a robust competition as the market landscape continues to be increase in fragmentation. Major players in the market are making large investments in reseach and development globally, finds Transparency Market Research (TMR). Some key players in the global osteoarthritis drugs market are Pfizer Inc., Horizon Pharma plc, Ferring B.V., Sanofi, Anika Therapeutics, Inc., Chugai Pharmaceutical Co., and Bioventus, Inc.

The global osteoarthritis drugs market is expected to be propel forward in the near future, thanks to a growing awareness of diseases like degenerative bone disease, increasing R&D, and growing geriatric population as well. The pharmaceutical industry is growing through a tough phase as several key patents have expired. On the other hand, the industry is also faced with opportunities to reduce manufacturing costs considerably, due to advancements like 3D printing, several lucrative outsourcing opportunities, and prospects like Nano technology. This is expected to act as a catalyst for innovation in the industry with several firms already raising the bar with new drug developments and vital modifications in processes.

Planning To Lay Down Future Strategy? Request Brochure Of Osteoarthritis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47571

The global osteoarthritis drugs market is projected to touch US$ 11,226.1 mn by 2026 end. However, due to patent expiry challenges and introduction of several generic versions driving down margins, the market is likely to expand at a single digit CAGR during the forecast period. Among various types of drugs in the market, the viscosupplementation agents are expected to dominate market growth, partly due to their high costs and partly due to growing demand for knee related arthritis treatments due to their effectiveness.

Growing Elderly Population a Major Driver of the Osteoarthritis Drugs Market

Osteoarthritis (OA) is an prevalent disease globally and it affects the elderly population quite severely. The condition is also life-threatening to many as it leads to impaired mobility leading to more potential accidents and financial constraints. However, the current crop of osteoarthritis drugs only offer pain mitigation and relief, but not a permanent solution. Additionally, osteoarthritis drugs also fail to halt disease progression. Hence, despite their lack of effectiveness and extreme high costs of viscosupplementation, the global osteoarthritis drugs market continues to grow. Moreover, the rising elderly population around the globe, and increasing reach of programs like Medicare in the US and privatized healthcare bill recently introduced in Australia, the osteoarthritis drugs market will result in several new opportunities for innovation.

Anti-Nerve Growth Therapy Promises a New Avenue for Growth

The global osteoarthritis market is witnessing several new product launches like increased investments, increasing prevalence of osteoarthritis due to growing obesity worldwide, and this has resulted in promising treatments like Anti- NGF treatments. NGF or Nerve Growth Factor is a promising therapy which can subside the progression of several arthritic conditions, and provides immense relief during chronic pain. Additionally, advent of other disease modifying osteoarthritis drug (DMOAD) also presents a new opportunity on the horizon. These drugs have proven to improve key functions like joints and promise to halt the progression of the disease as well. Nanobody is another promising treatment for arthritis.

To Obtain All-Inclusive Information On Forecast Analysis Of Osteoarthritis Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=47571

However, lack of seriousness in treating arthritis differently than conditions like old age is a major factor restraining the growth of the market. More awareness and more promising drugs can be major impetus for growth for the osteoarthritis drugs market in the near future.

Information provided in this review is obtained from a TMR report, titled, “Osteoarthritis Drugs Market (Drug Class - Corticosteroids, NSIADs and Others, Viscosupplementation Agents; Route of Administration - Oral, Parenteral, Topical; Distribution Channel - Hospital Pharmacies, Retail pharmacies, Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”

More Trending Reports by Transparency Market Research –

Digital Health Market –

https://www.prnewswire.com/news-releases/digital-health-market-to-attain-revenue-of-us536-6-billion-by-2025-due-to-growing-demand-for-advanced-devices-to-monitor-patients-says-tmr-300788873.html

N95 Mask Market –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=76860

0 notes

industryinsights-blog1 · 6 years

Text

Nanomedicine Market Size Worth $350.8 Billion By 2025 | CAGR: 11.2%

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/nanomedicine-market

Further key findings from the report suggest:

Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices

These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation

Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share

In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment

Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress

Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis

Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies

Asia Pacific is estimated to witness the fastest growth over the forecast period

Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.

Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck

Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

North America dominated the industry in 2016, accounting for a 42% of total revenue

Presence of key participants operating in the region are involved in collaborative activities are attributive for the largest share of North America in sector revenue

Access press release of this research report by Grand View Research: https://www.grandviewresearch.com/press-release/global-nanomedicine-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more Information: www.grandviewresearch.com

0 notes

rupalic · 3 years

Text

Isoflavones Market: Growth Opportunities and Recent Developments

The global isoflavones market is estimated to be valued at USD 1.2 billion in 2019 and is projected to grow at a CAGR of 4.7% to reach USD 1.5 billion during the forecast period. Growth in this industry is driven by the increasing incidences of chronic diseases, rising prevalence of cancer, technological advancements in the manufacturing of isoflavones, the rapidly increasing geriatric population and so on. By Source, the soy segment is expected to lead the isoflavones market. Prominent dietary sources of isoflavones include soy milk and plant-based alternatives. Several calcium-fortified soy drinks that are rich in fiber and proteins are given preference in countries such as Germany, France, and Switzerland. The consumption of soy isoflavones as food ingredients or food supplements reduces the risk of breast cancer and growth of cancer cells by reducing the cell mitosis process, which fuels the demand for soy as a major source of isoflavones. By application, the pharmaceutical segment is projected to account for the largest share during the forecast period. Based on application, the isoflavones market is segmented into pharmaceuticals, nutraceuticals, cosmetics, and food & beverages. The pharmaceuticals segment accounted for the largest share, owing to its therapeutic and functional properties; isoflavones are used in the treatment for chronic and cardiovascular diseases. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161667005 Key players in isoflavone market include Cargill (Germany), ADM (US), BASF (Germany), DSM (Netherlands), International Flavors and Fragrances (Frutarom) (US), Shanghai Freemen (US), Nexira Inc. (France), Bio-gen Extracts, Sikko Industries, SK Bioland (South Korea), BioMax (India), Avestia Pharma (India), NutraScience Labs (US), Tradichem S.L. (Spain), Nutra Green Biotechnology (China), Herbo Nutra (India), FutureCeuticals Inc. (US), Bio-gen Extracts (US), Xena Bio Herbals Pvt. Ltd. (India), Sikko Industries (India), Biomax (India), and Lactonova (India). North America to lead the market during the forecast period. The North American region accounted for the largest share of the isoflavones market. Increasing cases of obesity in North America increase the focus on weight management techniques & attracting consumers toward healthy and natural food products with natural ingredients, thereby propelling the demand for isoflavones in the region. Market Dynamics Driver: Prevalence of menopausal issues Women in their menopause stage experience various issues such as hot flashes, insomnia, and, in numerous cases, sexual dysfunction. Many women prefer supplements containing estrogen, which may significantly increase the risk of blood clots, stroke, or breast or uterine cancer. Thus, estrogen may not be an option for many women, depending on their health and family health history. Women are currently inclining toward supplements with naturally therapeutic ingredients to manage their menopause symptoms with fewer risks. In response to such changing preferences of women, supplement manufacturers have turned to natural alternatives. They have started utilizing soy isoflavones instead of estrogen, as it mimics the estrogen characteristics and provides estrogen effects that aid in reducing menopausal symptoms such as hot flashes and fatigue. Owing to the rising issues related to menopause and women’s inclination toward supplements with natural alternatives, the demand for isoflavones from the nutraceutical industry is projected to grow in the coming years Restraint: Stringent regulatory requirements Isoflavones come under the active pharmaceutical ingredient (API) category; hence, manufacturers have to follow the rules and regulations imposed for all API products. Pharmaceutical API manufacturers across the globe are witnessing a rise in the demand for APIs, which results in a positive outlook for the market. However, the increasing stringency of regulations is considered as a major restraint that may limit the growth prospects of the market. According to the report, “Fine chemicals stringent regulations prompt return of manufacturing to the west,” published by IHS Chemical Week in January 2015, the demand for APIs is expected to grow at a consistent rate, while the supply of APIs manufactured with international Good Manufacturing Practice (GMP) standards and world-class documentation is not keeping pace with this demand. Opportunity:Emerging technologies Some of the recent advancements in drug development include the use of nanotechnology for the synthesis of APIs. The emergence of nanoparticle technologies for efficient delivery of APIs shows promising potential as a novel and efficient approach. Nanobodies are similar to single-domain antibodies that can bind to specific antigens; however, they are much smaller in size than antibodies. Nanobodies are rapidly becoming an attractive technology platform for pharmaceutical development. Chitosan and Eudragit nanoparticles of Genistein, the predominant isoflavone found in soy products for cancer therapy, have been significantly evaluated for the treatment of chronic diseases in the past few years. The delivery of Genistein-loaded Chitosan and Eudragit S100 loaded polymeric nanoparticles has proven to be a feasible approach to treat cancer. Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=161667005 Similarly, bispecific antibodies, which can bind to two different epitopes either on the same or different target, are attracting the attention of market players. Such emerging technologies have the potential to create attractive opportunities for market players. Challenge: Less efficiency compared to alternatives Soy isoflavones can take several weeks or more to reach their maximal benefit. For example, as per Healthline Media (US), a 2015 review found that soy isoflavones take more than 13 weeks to reach just half of their maximum effect. Traditional hormones such as estrogen therapy, on the other hand, take about three weeks to show the same benefit. However, possible adverse effects such as heart attacks and strokes associated with conventional estrogen therapy are projected to enable pharmaceutical and nutraceutical manufacturers to opt for isoflavones derived from natural resources.

0 notes

globalrketresearchanalysis · 7 years

Text

Nanomedicine Market Is Probable To Augment Growth Over The Forecast Period.

The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc. Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

Browse full research report on Nanomedicine Market: www.grandviewresearch.com/industry-analysis/nanomedicine-market